Our findings are in concordance with other reports that demonstrate a dependence on AKT and mTOR signaling in T-ALL, but this study suggests that targeting AKT or mTOR in NOTCH-mutant T-ALL would be advantageous over PI3K inhibitors [33–37]. This evidence concerns the gene PIK3CG and acute lymphoblastic leukemia.